2-W continuous-wave and passively Q-switched Tm,Ho:YLF channeled waveguide laser at 2.05 µm
Optics Letters · 15.12.2024 · 49 (24) · 6968
DOI: 10.1364/ol.544317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optics Letters, online erschienen am 03.12.2024. Verfasst von Berke Ayevi und 5 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
We report on the operation of an efficient Tm,Ho:YLF depressed cladding, channeled waveguide laser in both continuous-wave (CW) and passively Q-switched (PQS) regimes, producing laser emission at the wavelength of 2.05 µm. The 70-µm diameter depressed cladding waveguide, fabricated using femtosecond laser inscription, had a low propagation loss value of 0.14 dB/cm and a refractive index contrast of 8.3 × 10 −4 . In the CW regime, the waveguide laser was excited at 780 nm, and an output power of up to 2 W was generated at the incident pump power of 4.14 W with a power slope efficiency of 50.0%. PQS operation was further realized by utilizing a Cr:ZnSe saturable absorber (SA), whereby the waveguide laser generated as short as 19.6-ns pulses with a power slope efficiency of 18.9%.
Zitieren
APA
Ayevi, B., Morova, Y., Morova, B., Damiano, E., Tonelli, M., & Sennaroglu, A. (2024). 2-W continuous-wave and passively Q-switched Tm,Ho:YLF channeled waveguide laser at 2.05 µm. Optics Letters, 49(24), 6968. https://doi.org/10.1364/ol.544317
Vancouver
Ayevi B, Morova Y, Morova B, Damiano E, Tonelli M, Sennaroglu A. 2-W continuous-wave and passively Q-switched Tm,Ho:YLF channeled waveguide laser at 2.05 µm. Optics Letters. 2024;49(24):6968. doi:10.1364/ol.544317
BibTeX
@article{Ayevi2024,
author = {Ayevi, Berke and Morova, Yagız and Morova, Berna and Damiano, Eugenio and Tonelli, Mauro and Sennaroglu, Alphan},
title = {2-W continuous-wave and passively Q-switched Tm,Ho:YLF channeled waveguide laser at 2.05 µm},
journal = {Optics Letters},
year = {2024},
volume = {49},
number = {24},
pages = {6968},
doi = {10.1364/ol.544317}
}
EUVIMED